4117 Stock Overview
Engages in the research, development, manufacture, and sales of in-vitro diagnostics in Taiwan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
General Biologicals Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$17.00 |
| 52 Week High | NT$30.20 |
| 52 Week Low | NT$16.90 |
| Beta | 1.63 |
| 11 Month Change | -7.10% |
| 3 Month Change | -13.04% |
| 1 Year Change | -39.50% |
| 33 Year Change | -58.49% |
| 5 Year Change | 100.00% |
| Change since IPO | 65.85% |
Recent News & Updates
Shareholder Returns
| 4117 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | -4.0% | 1.4% | 2.0% |
| 1Y | -39.5% | 1.3% | 31.8% |
Return vs Industry: 4117 underperformed the TW Biotechs industry which returned 1.3% over the past year.
Return vs Market: 4117 underperformed the TW Market which returned 31.8% over the past year.
Price Volatility
| 4117 volatility | |
|---|---|
| 4117 Average Weekly Movement | 2.9% |
| Biotechs Industry Average Movement | 4.4% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in TW Market | 8.1% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 4117 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 4117's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1973 | n/a | T.C. Lin | www.gbc.com.tw |
General Biologicals Corporation engages in the research, development, manufacture, and sales of in-vitro diagnostics in Taiwan and internationally. It offers ELISA and chemiluminescence immunoassay, molecular and cell diagnostic, and point of care testing services. The company also provides COVID-19, digital pathology, and contract development manufacturing organization solutions; blood screening services for hepatitis and HIV; and biomaterial, such as antibody biomaterials and human plasma.
General Biologicals Corporation Fundamentals Summary
| 4117 fundamental statistics | |
|---|---|
| Market cap | NT$1.03b |
| Earnings (TTM) | -NT$209.31m |
| Revenue (TTM) | NT$242.40m |
4.3x
P/S Ratio-4.9x
P/E RatioIs 4117 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4117 income statement (TTM) | |
|---|---|
| Revenue | NT$242.40m |
| Cost of Revenue | NT$188.67m |
| Gross Profit | NT$53.73m |
| Other Expenses | NT$263.04m |
| Earnings | -NT$209.31m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.44 |
| Gross Margin | 22.16% |
| Net Profit Margin | -86.35% |
| Debt/Equity Ratio | 344.3% |
How did 4117 perform over the long term?
See historical performance and comparison